Expression of Chemokine Receptors CXCR4 and CCR5 in HIV-1-infected and Uninfected Individuals
Overview
Authors
Affiliations
The chemokine receptors CXCR4 and CCR5 have been identified as major coreceptors for HIV-1 entry into CD4+ T cells. The majority of primary HIV-1 isolates in early disease use CCR5 as a coreceptor, whereas during disease progression with the emergence of syncytium-inducing viruses, CXCR4 is also used. We performed a cross-sectional study in which we evaluated the expression of two HIV-1 coreceptors, CCR5 and CXCR4, in whole blood samples taken from HIV-1-infected and uninfected individuals. We demonstrate that CXCR4 on CD4+ and CD8+ T cells, and CD14+ monocytes is significantly down-regulated, and CCR5 expression on CD4+ T cells is up-regulated in HIV-infected individuals compared with uninfected controls. Coreceptor expression correlated with the level of cellular activation in vivo in both HIV-infected and uninfected individuals, with CXCR4 being expressed predominantly on quiescent (HLA-DR-) T cells and CCR5 being expressed predominantly on activated (HLA-DR+) T cells. Lower expression of CXCR4 and higher expression of CCR5 on CD4+ T cells correlated with advancing disease. In addition, a tendency for greater activation of CXCR4+CD4+ T cells in patients with advanced disease was observed. Patients who harbored syncytium-inducing viruses, however, could not be distinguished from those who harbored nonsyncytium-inducing viruses based on the level of CD4+ T cell activation or chemokine receptor expression.
Immune Alterations and Viral Reservoir Atlas in SIV-Infected Chinese Rhesus Macaques.
Clain J, Picard M, Rabezanahary H, Andre S, Boutrais S, Goma Matsetse E Infect Dis Rep. 2025; 17(1).
PMID: 39997464 PMC: 11855486. DOI: 10.3390/idr17010012.
Modeling HIV-1 infection and NeuroHIV in hiPSCs-derived cerebral organoid cultures.
Donadoni M, Cakir S, Bellizzi A, Swingler M, Sariyer I J Neurovirol. 2024; 30(4):362-379.
PMID: 38600307 PMC: 11464638. DOI: 10.1007/s13365-024-01204-z.
Wahl A, Yao W, Liao B, Chateau M, Richardson C, Ling L Nat Biotechnol. 2023; 42(6):905-915.
PMID: 37563299 PMC: 11073568. DOI: 10.1038/s41587-023-01906-5.
van Eekeren L, Matzaraki V, Zhang Z, van de Wijer L, Blaauw M, de Jonge M Sci Rep. 2022; 12(1):11425.
PMID: 35794176 PMC: 9259737. DOI: 10.1038/s41598-022-15646-0.
Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.
Mohamed H, Gurrola T, Berman R, Collins M, Sariyer I, Nonnemacher M Front Immunol. 2022; 12():816515.
PMID: 35126374 PMC: 8811197. DOI: 10.3389/fimmu.2021.816515.